Literature DB >> 10405908

13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes.

B R Lee1, M E Jabbour, F F Marshall, A D Smith, T W Jarrett.   

Abstract

BACKGROUND AND
OBJECTIVE: Transitional cell carcinoma (TCC) of the renal collecting system traditionally has been managed by open nephroureterectomy with en bloc resection of a bladder cuff. However, for a select patient population with a solitary kidney or bilateral disease, the morbidity and mortality associated with chronic renal insufficiency and dialysis is deterring. In these situations, a more conservative approach such as antegrade percutaneous resection should be considered. The long-term disease-free outcome of percutaneous management in comparison with open nephroureterectomy has not been previously reported. We evaluated our experience with two surgical approaches to treat upper tract TCC: percutaneous resection and nephroureterectomy/nephrectomy to assess the clinical efficacy of these surgical modalities. PATIENTS AND METHODS: We retrospectively identified 162 patients who had clinically localized TCC of the upper urinary tract. Records were reviewed to identify those with 13-year follow-up (N = 110) in respect to tumor grade, stage, disease-free status, length of cancer-specific survival, and overall survival. Statistical analysis of the results of open nephroureterectomy/nephrectomy (N = 60) and percutaneous resection (N = 50) was performed using Kaplan-Meier survival curves and Student's t-test.
RESULTS: All patients had disease in clinical stage Ta through T3. During a mean follow-up of 46.6 (range 6-150) months, grade 1 disease demonstrated little invasive potential. Of the disease-specific deaths, 60% (17/26) were of patients with grade 3 lesions, with a mean cancer survival period of 15.2 months after the initial procedure. Disease-specific survival rates after open and percutaneous approaches for grade 2 disease were 53.8 and 53.3 months, respectively (P > 0.05).
CONCLUSIONS: Tumor grade appeared to be the most important prognostic indicator in patients with renal TCC regardless of the surgical approach. Grade 3 tumors were more aggressive, presenting in an advanced stage with invasion, and recurrences were usually associated with metastasis. In this population, nephroureterectomy is warranted if the patient is a surgical candidate. The percutaneous option for grade 1 or 2 disease may be extended beyond the population with solitary kidneys and a risk of chronic renal failure to be offered to healthy individuals with normal contralateral kidneys who are willing to abide by a strict and lengthy follow-up.

Entities:  

Mesh:

Year:  1999        PMID: 10405908     DOI: 10.1089/end.1999.13.289

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  16 in total

Review 1.  Lasers in percutaneous renal procedures.

Authors:  Nadya M Cinman; Sero Andonian; Arthur D Smith
Journal:  World J Urol       Date:  2009-06-02       Impact factor: 4.226

Review 2.  Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence.

Authors:  Luca Carmignani; Roberto Bianchi; Gabriele Cozzi; Angelica Grasso; Nicola Macchione; Carlo Marenghi; Sara Melegari; Marco Rosso; Elena Tondelli; Augusto Maggioni
Journal:  Rev Urol       Date:  2013

Review 3.  Nephron-sparing Management of Upper Tract Urothelial Carcinoma.

Authors:  Francesca Suriano; Tommaso Brancato
Journal:  Rev Urol       Date:  2014

4.  Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data.

Authors:  Goutham Vemana; Eric H Kim; Sam B Bhayani; Joel M Vetter; Seth A Strope
Journal:  Urology       Date:  2016-05-24       Impact factor: 2.649

Review 5.  [Endosopic organ-sparing treatment of urothelial tumors of the upper urinary tract: indications and results].

Authors:  M Hruza; C Stock; D Teber; J J Rassweiler
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

6.  Conservative nephron-sparing treatment of upper-tract tumors.

Authors:  Paul Smith; Juliette Mandel; Jay D Raman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

7.  Comprehensive management of upper tract urothelial carcinoma.

Authors:  Georgios Koukourakis; Georgios Zacharias; Michael Koukourakis; Kiriaki Pistevou-Gobaki; Christos Papaloukas; Athanasios Kostakopoulos; Vassilios Kouloulias
Journal:  Adv Urol       Date:  2008-12-10

8.  Endoscopic management of upper tract urothelial carcinoma.

Authors:  K Moore; J Khastgir; M Ghei
Journal:  Adv Urol       Date:  2009-01-04

9.  Endourologic management of upper tract transitional cell carcinoma following cystectomy and urinary diversion.

Authors:  Jeffrey John Tomaszewski; Marc Christopher Smaldone; Michael Cecil Ost
Journal:  Adv Urol       Date:  2008-12-28

10.  Conservative management of upper tract transitional cell carcinoma.

Authors:  Markian R Iwaszko; Amy E Krambeck
Journal:  Indian J Urol       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.